Board Meetings for AUROPHARMA
Detailed list of historic and upcoming board meetings.
| Symbol | Company | Meeting Date | Purpose | Description | Links |
|---|---|---|---|---|---|
| AUROPHARMA | Aurobindo Pharma Limited | 27 May 2023 | AUROBINDO PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 27-May-2023 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2023 . | Board Meeting Intimation | |
| AUROPHARMA | Aurobindo Pharma Limited | 09 Feb 2023 | Financial Results/Dividend | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday, February 9, 2023 to consider and approve inter alia, the following:1. Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2022 and2. Payment of Interim Dividend, if any, for the financial year 2022-23.Further to our letter dated December 29, 2022 informing about the closure of Trading Window of the Company from January 1, 2023 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2022, we inform you that the Trading Window will remain closed up to February 11, 2023 and shall be re-opened on February 12, 2023. | |
| AUROPHARMA | Aurobindo Pharma Limited | 12 Nov 2022 | Financial results | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that a Meeting of the Board of Directors of the Company will be held on Saturday, November 12, 2022 to consider and approve inter alia, the Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2022.Further to our letter dated September 28, 2022 informing the closure of Trading Window of the Company from October 1, 2022 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2022, we inform you that the Trading Window will remain closed up to November 14, 2022 and shall be re-opened on November 15, 2022. | |
| AUROPHARMA | Aurobindo Pharma Limited | 11 Aug 2022 | Financial results | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday, August 11, 2022 to consider and approve inter alia, the Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2022.Further to our letter dated June 28, 2022 informing the closure of Trading Window of the Company from July 1, 2022 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022, we inform you that the Trading Window will remain closed up to August 13, 2022 and shall be re-opened on August 14, 2022. | |
| AUROPHARMA | Aurobindo Pharma Limited | 30 May 2022 | Dividend/Financial results | We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on Monday, May 30, 2022 to consider and approve inter alia, the following:1. Standalone & Consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022 and2. Payment of Fourth Interim Dividend, if any, for the financial year 2021-22. Please note that the record date for the purpose of determining the entitlement of the equity shareholders for the aforesaid interim dividend, if declared, is fixed as Friday, June 3, 2022.Further to our letter dated March 29, 2022 informing the closure of Trading Window of the Company from April 1, 2022 until 48 hours from the date of declaration of the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022, we inform you that the Trading Window will remain closed up to June 1, 2022 and shall be re-opened on June 2, 2022. | |
| AUROPHARMA | Aurobindo Pharma Limited | 09 Feb 2022 | Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2021 and dividend | |
| AUROPHARMA | Aurobindo Pharma Limited | 08 Nov 2021 | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2021 and dividend | |
| AUROPHARMA | Aurobindo Pharma Limited | 12 Aug 2021 | Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2021 and dividend | |
| AUROPHARMA | Aurobindo Pharma Limited | 31 May 2021 | Financial Results | To consider and approve the financial results for the period ended March 31, 2021 | |
| AUROPHARMA | Aurobindo Pharma Limited | 10 Feb 2021 | Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2020 and dividend | |
| AUROPHARMA | Aurobindo Pharma Limited | 11 Nov 2020 | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2020 and dividend | |
| AUROPHARMA | Aurobindo Pharma Limited | 12 Aug 2020 | Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2020 and dividend | |
| AUROPHARMA | Aurobindo Pharma Limited | 03 Jun 2020 | Financial Results | To consider and approve the financial results for the period ended March 31, 2020 | |
| AUROPHARMA | Aurobindo Pharma Limited | 06 Feb 2020 | Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2019 and dividend | |
| AUROPHARMA | Aurobindo Pharma Limited | 12 Nov 2019 | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2019 and dividend |